3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Bevacizumab
55
Cetuximab
52
Fluorouracil
45
Oxaliplatin
39
Leucovorin
38
pembrolizumab
34
Specimen Handling
29
Irinotecan
24
Magnetic Resonance Spectroscopy
18
Biopsy
18
Nivolumab
17
Capecitabine
14
trifluridine tipiracil drug combination
13
HMPL-013
13
Folfox protocol
13
Panitumumab
12
Gemcitabine
12
Cisplatin
12
Carboplatin
11
encorafenib
9
balstilimab
9
Standard of Care
9
Pemetrexed
9
IFL protocol
9
Trifluridine
8
Paclitaxel
8
Early Intervention, Educational
8
130-nm albumin-bound paclitaxel
8
fludarabine
7
atezolizumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
tisotumab vedotin
×
90 days
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled